A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

561

Participants

Timeline

Start Date

March 2, 2016

Primary Completion Date

November 7, 2018

Study Completion Date

November 7, 2018

Conditions
Schizophrenia
Interventions
DRUG

ALKS 3831

Daily dosing

DRUG

Olanzapine

Daily dosing

Trial Locations (54)

10032

Alkermes Investigational Site, New York

10035

Alkermes Investigational Site, New York

Alkermes Investigational Site, Wards Island

11235

Alkermes Investigational Site, Brooklyn

11432

Alkermes Investigational Site, Jamaica

14615

Alkermes Investigational Site, Rochester

18104

Alkermes Investigational Site, Allentown

20016

Alkermes Investigational Site, Washington D.C.

30030

Alkermes Investigational Site, Decatur

30329

Alkermes Investigational Site, Atlanta

30912

Alkermes Investigational Site, Augusta

33136

Alkermes Investigational Site, Miami

33161

Alkermes Investigational Site, North Miami

33319

Alkermes Investigational Site, Lauderhill

33334

Alkermes Investigational Site, Oakland Park

33609

Alkermes Investigational Site, Tampa

39232

Alkermes Investigational Site, Flowood

44130

Alkermes Investigational Site, Middleburg Heights

44718

Alkermes Investigational Site, Canton

45417

Alkermes Investigational Site, Dayton

49503

Alkermes Investigational Site, Grand Rapids

60640

Alkermes Investigational Site, Chicago

63128

Alkermes Investigational Site, St Louis

63141

Alkermes Investigational Site, Creve Coeur

63368

Alkermes Investigational Site, O'Fallon

72211

Alkermes Investigational Site, Little Rock

72764

Alkermes Investigational Site, Springdale

75115

Alkermes Investigational Site, DeSoto

75243

Alkermes Investigational Site, Dallas

77030

Alkermes Investigational Site, Houston

78754

Alkermes Investigational Site, Austin

78759

Alkermes Investigational Site, Austin

89102

Alkermes Investigational Site, Las Vegas

90230

Alkermes Investigational Site, Culver City

90502

Alkermes Investigational Site, Torrance

90660

Alkermes Investigational Site, Pico Rivera

90703

Alkermes Investigational Site, Cerritos

90822

Alkermes Investigational Site, Long Beach

91206

Alkermes Investigational Site, Glendale

91950

Alkermes Investigational Site, National City

92056

Alkermes Investigational Site, Oceanside

92103

Alkermes Investigational Site, San Diego

92123

Alkermes Investigational Site, San Diego

92374

Alkermes Investigational Site, Redlands

92591

Alkermes Investigational Site, Temecula

92805

Alkermes Investigational Site, Anaheim

92845

Alkermes Investigational Site, Garden Grove

92868

Alkermes Investigational Site, Orange

94612

Alkermes Investigational Site, Oakland

98007

Alkermes Investigational Site, Bellevue

08009

Alkermes Investigational Site, Berlin

08053

Alkermes Investigational Site, Marlton

00918

Alkermes Investigational Site, San Juan

00926

Alkermes Investigational Site, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY

NCT02694328 - A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) | Biotech Hunter | Biotech Hunter